Abstract
Stem cell replacement has emerged as the novel therapeutic strategy for Parkinsons disease (PD). Control of motor behavior is lost in PD due to the selective degeneration of mesencephalic dopamine neurons (DA) in the substantia nigra. This progressive loss of DA neurons results in devastating symptoms for which there is no cure. Debilitating side effects often result from chronic pharmacological treatment, hence current investigations into cell transplantation therapy as a substitute and/or adjuvant to other therapeutics. Clinical trials with fetal DA tissue have provided evidence that cell transplantation could be a viable alternative. Limited availability of fetal tissue, combined with variable outcome led to emphasis on other sources of cells, such as stem cells. This review focuses on three stem cell sources (embryonic, neural, and adult mesenchymal). Also discussed is the molecular differentiation into mature DA neurons, the various protocols that have been developed to generate DA neurons from various stem cells, and the current state of stem cell therapy for PD.
Keywords: Parkinson's disease, dopamine, stem cells, development, transplantation, neural repair, cell replacement
Current Neurovascular Research
Title: Current Advances in the Treatment of Parkinsons Disease with Stem Cells
Volume: 4 Issue: 2
Author(s): Katarzyna A. Trzaska and Pranela Rameshwar
Affiliation:
Keywords: Parkinson's disease, dopamine, stem cells, development, transplantation, neural repair, cell replacement
Abstract: Stem cell replacement has emerged as the novel therapeutic strategy for Parkinsons disease (PD). Control of motor behavior is lost in PD due to the selective degeneration of mesencephalic dopamine neurons (DA) in the substantia nigra. This progressive loss of DA neurons results in devastating symptoms for which there is no cure. Debilitating side effects often result from chronic pharmacological treatment, hence current investigations into cell transplantation therapy as a substitute and/or adjuvant to other therapeutics. Clinical trials with fetal DA tissue have provided evidence that cell transplantation could be a viable alternative. Limited availability of fetal tissue, combined with variable outcome led to emphasis on other sources of cells, such as stem cells. This review focuses on three stem cell sources (embryonic, neural, and adult mesenchymal). Also discussed is the molecular differentiation into mature DA neurons, the various protocols that have been developed to generate DA neurons from various stem cells, and the current state of stem cell therapy for PD.
Export Options
About this article
Cite this article as:
Trzaska A. Katarzyna and Rameshwar Pranela, Current Advances in the Treatment of Parkinsons Disease with Stem Cells, Current Neurovascular Research 2007; 4 (2) . https://dx.doi.org/10.2174/156720207780637199
DOI https://dx.doi.org/10.2174/156720207780637199 |
Print ISSN 1567-2026 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5739 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Management of Obesity in Pregnancy
Current Women`s Health Reviews Recent Advances in Treatment Approaches to Gaucher Disease
Current Pharmaceutical Biotechnology Arterial Ischemic Stroke in Neonates and Children: Review and Current Issues
Current Pediatric Reviews Cardiovascular Disease in Systemic Lupus Erythematosus: Recent Data on Epidemiology, Risk Factors and Prevention
Current Vascular Pharmacology Editorial (Thematic Issue: G-protein Coupled Receptors in Vascular Biology: Implication in Health and Disease)
Current Vascular Pharmacology Sundowning Syndrome: A Possible Marker of Frailty in Alzheimer’s Disease?
CNS & Neurological Disorders - Drug Targets Fetal Origins of Cardiovascular Disease
Current Cardiology Reviews Smoking and Cardiovascular System: Cellular Features of the Damage
Current Pharmaceutical Design Green Tea Catechins and Cardiovascular Health: An Update
Current Medicinal Chemistry The Serpin Solution; Targeting Thrombotic and Thrombolytic Serine Proteases in Inflammation
Cardiovascular & Hematological Disorders-Drug Targets Neurological Aspects of Grief
CNS & Neurological Disorders - Drug Targets Apolipoprotein A-I/HDL Infusion Therapy for Plaque Stabilization-Regression: A Novel Therapeutic Approach
Current Pharmaceutical Design Lipoprotein-associated Phospholipase A2 and Coronary Heart Disease
Current Pharmaceutical Design Inhibition of the Calcineurin-NFAT Signalling Cascade in the Treatment of Heart Failure
Recent Patents on Cardiovascular Drug Discovery HMG-CoA Reductase Inhibitors (Statins) and their Drug Interactions Involving CYP Enzymes, P-glycoprotein and OATP Transporters-An Overview
Current Drug Metabolism Thioridazine: The Good and the Bad
Recent Patents on Anti-Infective Drug Discovery A Review of Sirt1 and Sirt1 Modulators in Cardiovascular and Metabolic Diseases
Recent Patents on Cardiovascular Drug Discovery Chemical Biology: Past, Present and Future
Current Chemical Biology COVID-19: Are Experimental Drugs a Cure or Cause?
Current Drug Safety Taste and Hypertension in Humans: Targeting Cardiovascular Disease
Current Pharmaceutical Design